



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 8th May 2017

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the April 2017 Medicines Group meeting were approved and will be circulated.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full applications

• **Sodium Hyaluronate 40mg/50ml bladder instillation (Cystistat[®])**

Cystistat[®] is a Class 3 Medical Device. Requested by the Urology Team at WMUH Site for the temporary replacement of the glycosaminoglycan (GAG) layer in the bladder.

Cystistat has been shown to be effective in the treatment of Interstitial Cystitis (IC), Recurrent Bacterial Cystitis (RBC) and Radiation-Induced Cystitis (RIC). Hyacyst[®] remains the first line agent. The intention is to use this agent to treat a cohort of existing patients at WMUH Site who have already been started on a 12 month course of Cystistat[®]. All new patients going forward will be treated with Hyacyst[®]. The request also extended to adding it to the formulary as a 2nd line agent for patients who fail Hyacyst[®] therapy.

Decision: Approved for treatment of the cohort of existing patients who have already been started on a 12 month course of Cystistat[®]. Approval was not granted for it to be added to the formulary as a 2nd line agent for patients who fail Hyacyst[®] therapy.

Action: Formulary to be updated to list this agent as a generic medicine - Hyacyst[®] is currently listed as a branded medicine. It should be prescribed as a generic product and the brand of lowest acquisition cost supplied.

Ex-Panel Requests

• **Omeprazole 10mg/5ml and 20mg/5ml Oral Solution (Aclomep[®])**

This is a Special (Category A Unlicensed Medicinal Product).

Omeprazole oral solution will replace the current use of omeprazole Losec[®] capsules dissolved in sodium bicarbonate 8.4% solution.

There is still a need to keep both on the formulary as due to it being a Special there can be manufacturing delays with this product

As well as the liquid being more convenient for parents/carers to administer to paediatric patients, it is also a cost saving, particularly since the expiry date on the oral bicarbonate is only 3 days once opened.

Omeprazole 10mg/5ml (Aclomep[®]) liquid, 100ml - £57 per bottle

Omeprazole 20mg/5ml (Aclomep[®]) liquid, 100ml - £68 per bottle

Omeprazole Losec[®] capsules - £10 per pack of 28 capsules

Sodium bicarbonate 8.4% oral solution (3 day expiry), 100ml - £42 per bottle

Introduction of the product has been supported by prescribing information which has been distributed to all paediatric and neonatal consultants.

Decision: Approved for addition to the formulary

NICE TA Approved Requests

• **Sofosbuvir 400mg / Velpatasvir 100mg Tablets (Epclusa[®]) (Gilead) - In line with NICE TA430**

For use in line with NICE TA430 (Sofosbuvir–Velpatasvir for treating chronic Hepatitis C.

Decision: Approved for addition to the formulary



Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

Pharmacoeconomic Board Requests

- **Ustekinumab IV for Crohn's Disease - IFR form**

Requested by the Gastroenterology Team for a patient with Crohn's Disease.

Approved by the Pharmacoeconomic Board on 06/04/17.

Decision: Noted

4.2 Trust Medicines Policy

Nil

4.3 Medicines Optimisation

- **Trust PCA Policy**

Updated Trust PCA Policy that has been harmonised for use across both hospital sites.

Key stakeholders include: Medical, Nursing and Pharmacy specialists from Anaesthetics and Pain Management.

Decision: Approved

- **Trust Medicines Management Annual Report 2016-17**

This report summarises the activities of groups responsible for the management of medicines at Chelsea and Westminster Hospital NHS Foundation Trust, describes developments throughout the 2016-17 year and reports on results of external assessments.

Decision: Approved

- **New non-urgent out-patient dispensing at CWH Site**

This item related to a letter from NWL CCG relating to stopping new non-urgent out-patient dispensing at CWH Site in line with existing WMUH policy.

Decision: Noted

- **NHS England letter re. Individual Funding Requests - Continuation of funding following initial approval**

Letter from NHS England re. Individual Funding Requests relating to treatments commissioned by NHS England Specialised Services: Continuation of funding for medicines for long term conditions following initial approval.

Decision: Noted

- **NHS England letter re. Individual Funding Requests - Continuation of funding for CDF/NICE chemotherapy following a break in treatment**

Letter from NHS England re. Individual Funding Requests relating to treatments commissioned by NHS England Specialised Services: Continuation of funding for CDF/NICE chemotherapy following a break in treatment.

Decision: Noted

- **NHS England Letter re. Biosimilar Rituximab**

Letter from NHS England re. Biosimilar Rituximab

Decision: Noted

- **NHS England letter re. Regional Medicines Optimisation Committees**

Letter from NHS England re. Regional Medicines Optimisation Committees.

Decision: Noted

4.4 NICE TA Guidance

NICE TA Guidance - April 2017

6 Appraisals were published in April 2017



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

TA438 - Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Nil - No recommendation

TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Update to formulary to indicate that Cetuximab is now used in line with NICE TA439.

TA440 - Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Add Daclizumab to the Trust Medicines Formulary following receipt of a completed and signed application from the Neurology Team.

TA441 - Daclizumab for treating relapsing–remitting multiple sclerosis
Action: Add Daclizumab to the Trust Medicines Formulary as a completed and signed application from the Neurology Team has been received. Form to be included in the June papers for noting.

TA442 - Ixekizumab for treating moderate to severe plaque psoriasis
Add Ixekizumab to the Trust Medicines Formulary following receipt of a completed and signed application from the Dermatology Team.

TA443 - Obeticholic acid for treating primary biliary cholangitis
Add to the Trust Medicines Formulary following receipt of a completed and signed application from the Gastroenterology Team.

4.5 IVIG Update

- **IVIG requests**

April 2017

CWH Site

There were 17 IVIG issues, with 4 new requests

WMUH Site

There were 17 IVIG issues, with 4 new requests

Decision: Approved

4.6 Items for noting

- **MHRA Update - April 2017**

Decision: Noted

4.7 Meeting minutes for noting

Nil

4.8 Additional papers to go to Trust patient Safety Group

Nil

5. Any other business

6. Date of next meeting



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Date: Monday 26th June 2017

Time: 8am-9am

Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)

Closing date: 2nd June 2017